Newsletter

Stay up to date on all things Crohn's Disease. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Early MRI Prediction of Crohns

September 12, 2019

Overview

Researchers at the Children’s Hospital Medical Center, Cincinnati are translating noncontrast, novel Magnetic Resonance Imaging (MRI) techniques for detecting and measuring intestinal inflammation. The clinical trial also attempts to predict a response to medical therapy in small bowel Crohn’s disease (CD). 

 

Study Information

The study will consist of two groups: a control group of healthy subjects and a group of newly diagnosed Crohn’s patients. MR imaging will be used as an intervention to uncover the differences in subjects of both groups. The sessions will last 30-45 minutes with the purpose of predicting the therapeutic response in Crohn’s patients.

 

Inclusion Criteria

Healthy Control Group

  • Able to tolerate up to 45 minutes in an MRI scanner

Newly Diagnosed Crohn’s Group

  • Newly diagnosed small bowel Crohn’s disease
  • Expected to receive infliximab or other anti-Tumor Necrosis Factor (anti-TNF) medical therapy
  • Between 11 to 25 years old and able to assent/consent
  • Available for follow-up MRI at 4-weeks and 6-months after start of treatment,
  • Able to tolerate up to 45 minutes in an MRI scanner.

 

Exclusion Criteria

Healthy Control Group

  • Inability to obtain assent/consent,
  • Inability to tolerate 45 minutes in an MRI scanner,
  • Contraindication to MRI (e.g., MRI incompatible implant or support device),
  • Previous (remote) diagnosis or treatment of inflammatory bowel disease or other intestinal disease,
  • History of intra-abdominal surgery, including surgery on the intestine,
  • Pregnancy. Point-of-care urine pregnancy testing will be performed on all female study participants of reproductive potential (pediatric and adult) prior to each research MRI exam.

Newly Diagnosed Crohn’s Group

  • Inability to obtain assent/consent
  • Inability to tolerate 45 minutes in an MRI scanner
  • Contraindication to MRI (e.g., MRI incompatible implant or support device)
  • Previous (remote) diagnosis or treatment of inflammatory bowel disease
  • History of intra-abdominal surgery, including surgery on the intestine
  • Known bleeding disorder/coagulopathy
  • Pregnancy

 

Locations

You may participate in this study at Cincinnati Children’s Hospital Medical Center in Cincinnati, Ohio, United States, 45229. If you have any questions or concerns, feel free to contact Becky Imbus, BA at 513-636-9403 or at rebecca.imbus@cchmc.org

 

Sponsors/Collaborators

This clinical trial is sponsored by Children’s Hospital Medical Center, Cincinnati with Jonathan R Dillman, MD, MSc as the Principal Investigator.

Clinical Trials

View All Clinical Trials

The Biologic Onset of Crohn’s Disease: A Screening Study in First Degree Relatives

Early, aggressive diagnostic and therapeutic approaches have proven to improve chances of success in treating many…

Corticosteroid Dosage for Crohn’s Disease Flare

The Corticosteroid Dosage for Crohn’s Disease Flare clinical trial compares fixed dosing and weight-based…

Safety and Tolerability of Vorinostat for the Treatment of Moderate-to-Severe Crohn’s Disease

Since the inflammatory bowel disease of Crohn’s disease has no cure, researchers are always attempting to uncover…

Clinical Hypnosis in Pediatric Crohn’s Disease

Certain therapies may improve physical and psychosocial outcomes in patients with Crohn’s Disease. Among these…

FMT in Pediatric Crohn’s Disease

This study’s goal is determining the safety of multiple factors that indicate remission in Children from Cron’s…

Autologous Stem Cell Transplant for Crohn’s Disease

Although frequently ineffective, immune cell suppression therapy is widely used to treat Crohn’s disease, an…

Make a comment and share this article on your profile.

Write a comment for your publication

Successfully Shared!

View on my Profile

Send this to a friend